Loading...
XNYSENZ
Market cap38mUSD
Jan 06, Last price  
0.72USD
1D
2.21%
1Q
-35.44%
Jan 2017
-89.39%
Name

Enzo Biochem Inc

Chart & Performance

D1W1MN
XNYS:ENZ chart
P/E
P/S
1.19
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
1.40%
Rev. gr., 5y
-17.03%
Revenues
32m
+2.72%
43,402,60039,826,00052,908,00077,795,00089,572,00097,082,000102,029,000103,083,00093,707,00095,947,00097,599,000102,773,000107,804,000104,713,00081,170,00076,021,000117,731,000107,071,00031,061,00031,907,000
Net income
-26m
L
3,004,000-15,667,000-13,260,000-10,653,000-23,564,000-22,233,000-12,960,000-39,269,000-18,237,000-9,977,000-2,285,00045,286,000-2,504,000-10,321,000-98,781,000-33,890,0003,425,000-22,578,00020,288,000-26,078,000
CFO
-26m
L-28.98%
12,828,500-10,125,000-3,766,000-8,564,000-11,477,000-13,464,000-8,326,000-5,972,000-10,016,000-1,697,000-3,700,00053,126,000-205,000-2,735,0004,806,000-17,179,000387,000-16,590,000-36,976,000-26,259,000
Dividend
Jun 29, 19950.0661 USD/sh
Earnings
Mar 11, 2025

Profile

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
IPO date
Jun 13, 1980
Employees
465
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
31,907
2.72%
31,061
-70.99%
107,071
-9.05%
Cost of revenue
41,640
50,946
123,155
Unusual Expense (Income)
NOPBT
(9,733)
(19,885)
(16,084)
NOPBT Margin
Operating Taxes
12,299
4,317
Tax Rate
NOPAT
(9,733)
(32,184)
(20,401)
Net income
(26,078)
-228.54%
20,288
-189.86%
(22,578)
-759.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
386
28
BB yield
-0.53%
-0.02%
Debt
Debt current
917
1,960
3,742
Long-term debt
5,836
10,729
33,126
Deferred revenue
Other long-term liabilities
2,266
(3,160)
Net debt
(45,618)
(74,684)
10,265
Cash flow
Cash from operating activities
(26,259)
(36,976)
(16,590)
CAPEX
(545)
(2,760)
(3,472)
Cash from investing activities
(545)
98,980
25,223
Cash from financing activities
(4,193)
(1,125)
(241)
FCF
(8,224)
(4,520)
(26,516)
Balance
Cash
52,371
82,373
21,603
Long term investments
5,000
5,000
Excess cash
50,776
85,820
21,249
Stockholders' equity
(292,022)
(265,973)
(285,000)
Invested Capital
353,909
338,081
360,049
ROIC
ROCE
EV
Common stock shares outstanding
50,902
49,160
48,594
Price
1.14
-22.97%
1.48
-37.55%
2.37
-27.30%
Market cap
58,028
-20.24%
72,757
-36.83%
115,168
-26.90%
EV
12,410
(1,927)
125,433
EBITDA
(8,461)
(17,203)
(13,257)
EV/EBITDA
0.11
Interest
197
159
Interest/NOPBT